GuoLine Advisory Pte Ltd Purchases Shares of 25,900 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GuoLine Advisory Pte Ltd purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 25,900 shares of the biopharmaceutical company’s stock, valued at approximately $24,928,000. Regeneron Pharmaceuticals makes up about 3.0% of GuoLine Advisory Pte Ltd’s portfolio, making the stock its 18th largest position.

A number of other hedge funds have also modified their holdings of REGN. Norges Bank bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $932,571,000. International Assets Investment Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 76,169.5% in the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after purchasing an additional 590,314 shares in the last quarter. Global Assets Advisory LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $339,594,000. First Trust Advisors LP lifted its holdings in shares of Regeneron Pharmaceuticals by 115.2% in the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after purchasing an additional 195,902 shares in the last quarter. Finally, abrdn plc lifted its holdings in shares of Regeneron Pharmaceuticals by 552.8% in the fourth quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after purchasing an additional 186,215 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The disclosure for this sale can be found here. Insiders have sold a total of 61,971 shares of company stock valued at $61,217,654 in the last 90 days. 7.48% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $1,229.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday. TD Cowen upped their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Argus upped their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. upped their target price on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $1,015.91.

Regeneron Pharmaceuticals Stock Up 0.0 %

REGN stock traded up $0.09 during mid-day trading on Friday, reaching $1,050.95. 276,229 shares of the company traded hands, compared to its average volume of 476,350. The stock has a market cap of $115.80 billion, a price-to-earnings ratio of 31.04, a P/E/G ratio of 2.21 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $688.52 and a fifty-two week high of $1,081.17. The firm’s 50 day moving average price is $978.05 and its 200 day moving average price is $948.28.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.